Business Context and Reporting Period
Company: Innate Pharma SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Half-Year ended June 30, 2025
Filing Date: September 17, 2025
Principal Executive Office: Marseille, France
This filing incorporates by reference the H1 2025 Half-Year Financial Report (Exhibit 99.2) into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided text contains only the cover page and signature block of the Form 6-K. It references the Half-Year Financial Report as Exhibit 99.2 but does not include the financial data within this text.
- Revenue: Not provided in source text.
- Profit/Loss: Not provided in source text.
- Cash Flow: Not provided in source text.
- Margins: Not provided in source text.
- Debt and Liquidity: Not provided in source text.
Material Changes
The filing text does not provide specific financial figures or operational data to compare against prior periods. Consequently, no material changes in revenue, profit, or cash flow can be identified from the provided content.
Guidance, Outlook, and Risks
The provided text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items are expected to be located within the referenced Exhibit 99.2 (H1 2025 Half-Year Financial Report), which is not included in the input.
Investor Verification Checklist
- Access Exhibit 99.2: Retrieve the full "H1 2025 Half-Year Financial Report" to obtain actual financial statements.
- Verify Statutory Auditors' Review: Note that the Statutory Auditors' Review Report is explicitly excluded from the incorporation by reference in this filing; investors should locate the full audit report separately if required.
- Check Registration Statements: Confirm the status of the Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) to understand how this report impacts capital raising activities.
- Confirm CEO Authorization: The report is signed by Jonathan Dickinson, Chief Executive Officer, on September 17, 2025.